Anixa Biosciences (NASDAQ:ANIX – Get Free Report) and Immatics (NASDAQ:IMTX – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability and valuation.
Insider & Institutional Ownership
29.1% of Anixa Biosciences shares are owned by institutional investors. Comparatively, 64.4% of Immatics shares are owned by institutional investors. 26.4% of Anixa Biosciences shares are owned by company insiders. Comparatively, 3.3% of Immatics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Analyst Ratings
This is a breakdown of recent ratings and price targets for Anixa Biosciences and Immatics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Anixa Biosciences | 1 | 1 | 3 | 0 | 2.40 |
| Immatics | 1 | 0 | 7 | 0 | 2.75 |
Anixa Biosciences currently has a consensus target price of $8.00, indicating a potential upside of 201.89%. Immatics has a consensus target price of $19.67, indicating a potential upside of 193.40%. Given Anixa Biosciences’ higher probable upside, research analysts plainly believe Anixa Biosciences is more favorable than Immatics.
Valuation and Earnings
This table compares Anixa Biosciences and Immatics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Anixa Biosciences | $210,000.00 | 438.64 | -$10.93 million | ($0.32) | -8.28 |
| Immatics | $54.60 million | 16.78 | -$222.26 million | ($1.86) | -3.60 |
Anixa Biosciences has higher earnings, but lower revenue than Immatics. Anixa Biosciences is trading at a lower price-to-earnings ratio than Immatics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Anixa Biosciences and Immatics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Anixa Biosciences | N/A | -76.59% | -67.80% |
| Immatics | -495.71% | -47.41% | -39.45% |
Risk & Volatility
Anixa Biosciences has a beta of 0.47, indicating that its stock price is 53% less volatile than the S&P 500. Comparatively, Immatics has a beta of 1.36, indicating that its stock price is 36% more volatile than the S&P 500.
Summary
Immatics beats Anixa Biosciences on 8 of the 14 factors compared between the two stocks.
About Anixa Biosciences
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
About Immatics
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
Receive News & Ratings for Anixa Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anixa Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
